Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

13.6K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
13.6K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

2.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
2.1K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

2.2K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
2.2K
Preclinical Development: Overview01:28

Preclinical Development: Overview

6.6K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.6K
Prodrugs01:30

Prodrugs

4.8K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
4.8K
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Perceptions of the Values and Outcomes to Improve Cancer Experiences (VOICE) tool: a digital values-clarification instrument and tailored summary report for older adults with advanced cancer.

Journal of patient-reported outcomes·2026
Same author

Navigating Variability in Prostate RT Planning: Real-Time Insights for Human-Centered CDS Design.

AMIA ... Annual Symposium proceedings. AMIA Symposium·2026
Same author

Design approaches for developing quality checklists in healthcare organizations: A scoping review.

PLOS digital health·2025
Same author

Towards better understanding of factors contributing to medical physicist well-being in academic medical centers: A systems-analysis approach.

Journal of applied clinical medical physics·2025
Same author

Effect of Tailored Coaching on Physicians' Electronic Health Record Proficiency and User Experience: A Randomized Crossover Study.

Mayo Clinic proceedings. Digital health·2025
Same author

Identifying Contextual Workplace Stressors in a Division of Plastic and Reconstructive Surgery.

Plastic and reconstructive surgery. Global open·2025

Related Experiment Video

Updated: Apr 19, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.3K

Advancing drug discovery: a pharmaceutics perspective.

Elizabeth Kwong1

  • 1Kwong Eureka Solutions, Quebec, Canada.

Journal of Pharmaceutical Sciences
|December 9, 2014
PubMed
Summary
This summary is machine-generated.

The current drug discovery process is fragmented, hindering R&D productivity. This commentary proposes a 5-point plan from a pharmaceutics perspective to improve drug candidate selection and development.

Keywords:
Drug Design; ADMET propertiesMADdevelopability risk assessmentdrug-like propertiesin-silico modeling; in-vitro models;target therapeutic profile (TPP)operating models in discoveryphysicochemical propertiesrule of five

More Related Videos

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

5.7K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.7K

Related Experiment Videos

Last Updated: Apr 19, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.3K
Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

5.7K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.7K

Area of Science:

  • Pharmaceutical Sciences
  • Drug Discovery and Development

Background:

  • Current drug discovery practices are fragmented, lacking a unified approach to address challenges.
  • Existing processes and drug-likeness criteria are perceived as inadequate for future research and development (R&D) productivity.

Purpose of the Study:

  • To analyze current practices for identifying successful drug development candidates.
  • To propose a 5-point "must do" list to advance drug discovery from a pharmaceutics viewpoint.

Main Methods:

  • Analysis of existing industry practices in drug discovery candidate selection.
  • Development of a 5-point framework based on pharmaceutics principles.

Main Results:

  • Identified fragmentation and perceived "broken" processes in current drug discovery.
  • Formulated a 5-point list addressing ideal discovery team models, candidate profiles, building blocks, and risk assessment.

Conclusions:

  • A unified and well-defined approach is crucial for advancing drug discovery.
  • The proposed 5-point list offers a practical framework to enhance R&D productivity and improve drug candidate success rates.